Background/Aims: Gastric neuroendocrine tumors (G-NETs) are uncommon neoplasms that can present with or without clinical symptoms. In this study, we evaluated the incidence, prognosis, and temporal trends of G-NETs. Methods: We analyzed all cases of G-NETs registered in the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2014. Incidence was estimated by age and joinpoint analyses. Survival rates were calculated and survival trends over time were evaluated.
Gastric Neuroendocrine Tumors (G-
Nets
Introduction
Neuroendocrine tumours (NETs), known historically as carcinoid tumors, were first described by Lubarsch in 1888. These tumors are distributed throughout the body but are mainly found within the gastrointestinal (GI) tract [1] [2] [3] . Using data gathered from 1973 to 2004 from an epidemiological database in the United States, the Surveillance Epidemiology and End Results (SEER) study reports the incidence of NETs as 5.25 per 100.000 persons [4] . The incidence and prevalence of these tumors have been increasing in recent decades [5] . Widespread endoscopic screening, increased awareness of the neuroendocrine histology, and/or improved data capture likely have contributed to the early detection of tumors.
The treatment and the prognosis of patients with NET depend on the grade of differentiation and the stage of the tumor. For example, well-differentiated NETs can be effectively treated by somatostatin analogues, whereas the poorly differentiated NETs generally require more aggressive treatment such as surgery and chemotherapy [5] . New drugs, such as some tyrosine kinase inhibitors, have demonstrated a benefit on overall survival for well-differentiated NETs, but they have yet to be approved for the regulatory agencies [5] [6] [7] . In the same way, the prognosis of patients is better if NET is diagnosed at early stage than those at advanced stage [8] .
NETs of the stomach are rare and comprise about 0.1-0.6% of all gastric cancers [9] , and represent about 7% to 8% of all NETs [1, 10] . In fact, NETs-GI is a heterogeneous group of tumors which present with variety of clinical symptoms. Multiple factors may influence the malignant potential of the NETand the tumor site is one of pivotal factors determined the malignant potential of the tumor. There is few information available about the incidence and survival changes of G-NETs in the past decades. Moreover, in many published trials, G-NETs are lumped together with other GI-NETs and the results are difficult to analyze.
Hence, in this study, we estimate the incidence of NETs arising in the stomach in the SEER database. We also report the survival changes in 1975-2014 and the prognostic factor for survival after surgery for 1975-2012.
Materials and Methods

Patients
Two cohorts of patients with microscopically confirmed G-NETs were created using the SEER database (additional inclusion and exclusion criteria detailed below). This study was approved by the Review Board of Minhang Hospital, Fudan Universiy.
Cohort to Estimate G-NETs Incidence: SEER 9, 1975 SEER 9, -2014 One cohort, created to estimate long-term incidence, included G-NETs diagnosed in SEER 9 registries from 1975 to 2014. All cases with unknown age at time of diagnosis were excluded for the incidencecalculated as age-adjust incidence. The diagnosis of G-NETs was based on CS Schema v0204+ which classification as NETstomach. The NETstomach coding is equivalent with 8153/3: Gastrinoma, malignant, 8246/3: Neuroendocrine carcinoma, NOS, and 8249/3: Atypical carcinoid tumor based on International Classification of Diseases for Oncology, Third Edition (ICD-O-3). No other restrictions were applied. SEER 18, 1973 SEER 18, -2012 A second cohort was created to estimate the use of surgical therapy and survival information. Data for the SEER 18 registries, covering 28% of the US population, were selected to allow for subtype analyses while maintaining a consistent population. Cases were eligible if diagnosed from 1973 to 2012 with G-NETs. In order to guarantee a sufficient follow-up time, patients diagnosed after 2012 were excluded from the analyses. Cases with no survival information were excluded from the study.
Cohort to Estimate the Treatment and Survival of G-NETs:
Statistical Analyses
Incidence was estimated as diagnoses per 1 000 000 patients per year (SEER*Stat software, version 8.3.4, Information Management Services, Incorporated, Calverton, MD). Changes in incidence were assessed and fit (Joinpoint Regression Program version 4.2, Information Management Services, Incorporated, Calverton, MD) using log-linear models and annual percentage changes (APCs) estimated for the final, best fitting model. Differences in trends were also assessed [11] . SEER 9 registry data from 1975 to 2014 was used to estimate long-term trends.
Cellular Physiology and Biochemistry
Because a unified staging system for NETs is lacking, the SEER staging system was used for analysis. Tumors were classified as localized, regional, or distant. A localized NET was defined as an invasive neoplasm confined entirely to the organ of origin. A regional NET was defined as a neoplasm that (1) extended beyond the limits of the organ of origin directly into surrounding organs or tissue, (2) involved regional lymph nodes, or (3) fulfilled both of the aforementioned criteria. Finally, a distant NET was defined as a neoplasm that spread to parts of the body remote from the primary tumor [12] .
There is no accepted uniformed grading system for malignant NETs. Pathologists in the United States typically use the terms "carcinoid tumor" to denote well-differentiated NETs (G1). The term "atypical carcinoid" is frequently used to describe a moderately differentiated carcinoid and is classified as G2 tumor, poorly differentiated tumors are classified as G3 tumors, and anaplastic tumors are classified as G4 tumors [12] .
Survival analyses were conducted using the SPSS 17.0 statistical software package for the SEER18 cohort, diagnosed 1975-2012. Survival curves were plotted by Kaplan-Meier method and compared by logrank test. The significance of various survival-related variables was assessed by Cox regression model in the multivariate analysis. P < 0.05 was considered statistically significant. (Fig. 1) .
Results
G-NETs Incidence
At the same time, the incidence of systemic NETs presentations increased from 15.82 in 1975 to 78.85 in 2014, with an APC of increased at19.5% (95% CI= 0.5% to 42.1%, P < 0.001) from 1983 to 1986, 4.7% from 1986 to 2003(95% CI= 4.3% to 5.1%, P < 0.001) and 3.3% from 2003 to 2014 (95% CI=2.8% to 3.8%, P < 0.001), but there was no significant change in incidence from 1975 to 1983. 
G-NETs Five-Year cause specific Survival
For the number of patients diagnosed with G-NETs was small in the first decade since 1973. We used the SEER18 cohort to compare the survival rate improvement in the past 40 years. The cohort was divided into four subgroups by every ten years.
A total 3, 740 patients were included in the study, including 1497 male and 2243 female patients. The patients' characteristics were summarized in Table 1 . Five-year cause specific survival for G-NETs improved markedly from the first 10 years to latest 10 years. For cases diagnosed between 1973 and 1982, fiveyear survival was 62.8% ± 7.0% (Standard error, SE) and increased to 86.7% ± 0.7% for cases diagnosed between 2003 and 2012 (P < 0.001) (Fig. 2A) . Improvement in survival was slightly for systemic NETs, increasing from 70.63% ± 1.02% to 73.59% ± 0.38% for the same respective time periods (P<0 .05).
Five-year survival tended to be increased significantly for those presenting with Localized stage. The 5-year CSS was 90.9%, 89.6%, 93.2%, 96.8% for those diagnosed among 1973-1982, 1983-1992, 1993-2002, 2003-2012 (χ 2 =21..617, P<0.001) (Fig. 2B) . Although there was apparent improvement in survival for patients at Regional stage, but the difference was not statistical (5-year CSS was 34.3%, 53.3%, 42.6%, 59.9 % for the same respective time periods, χ 2 =5.678, P=0.128) (Fig. 2C) . The difference for patients at Distant stage is also not statistical significance (χ 2 =2.145, P=0.543) (Fig. 2D ).
Factors associated with prognosis of G-NETs
We found several factors, including years of diagnosis (P <0.001), gender (P <0.001), age at diagnosis (P <0.001), marital status (P <0.001), grade (P <0.001), tumor size (P Table 2) . As anticipated, large tumor size, elder patients, poor differentiate grade, and non-surgical therapy were validated as independent prognostic factor for G-NETs. Interestingly, female and unmarried patients were unfavorable prognostic factors for those patients.
Discussion
In present study, we took advantage of the vast amount of data from the SEER Program to examine the largest series of G-NET cases reported to date with a focus on incidence, prevalence, and prognostic factors. Similar to those of previous reports on systematic NETs [3] [4] [5] , our results indicated a significant increase in the reported incidence of NETs through the years. This increase was likely due to the improvements in classification of these tumors. Also, widespread use of endoscopy for cancer screening contributed to the increase in reported incidence of digestive tract NETs [4] . Despite this, widespread use of gastric acid inhibitors such as proton pump inhibitors, the changes of lifestyle may also be attributed to the increasing incidence [1, 13] .
Despite the fact that the annual prevalence of G-NENs has been increased globally in recent decades, data on factors associated with G-NENs prognosis has been poorly described, because of their rarity and with a spectrum of organic behaviors from benign to malignant [14] . Thus, our study provided comprehensive information on the prognosis of G-NENs with a large sample. Some findings in present study is very interesting. First, there was an apparently improvement in survival in the study periods. Surgical removal of tumors is the only potentially curative approach for G-NETs. Even in the presence of distant metastases, gastric surgery may be benefit [15] [16] [17] . Management dilemmas may be posed by the usually for G-NET at localized or distant stage. The advent of somatostatin and its analogues has generated new prospects for medical treatment of SRS-positive metastatic NETs. Ferraro et al. showed that administration of octreotide controlled the growth of ECL cells in the setting of atrophic gastritis-related hypergastrinemia [18] . Other investigators have shown that somatostatin analogues could induce regression of both hypergastrinemia-related [19] and sporadic [20] gastric NETs. It appears that somatostatin analogues are well suited for the management of metastatic gastric carcinoid, as they exert inhibitory action on both the trophic stimulus (gastrin) and the tumor itself. Various chemotherapeutic agents alone or in combination have been employed for treating metastatic G-NETs. Treatment with cisplatin plus irinotecan was effective against G-NET, with a high response rate and prolonged lifetime [21] . The combination of cisplatin with etoposide maybe the best choice for poorly differentiated G-NET [22] . Selecting the most effective agents using chemosensitivity assay to determines how effective specific chemotherapy agents are against an individual patient's cancer cells is a promising technique currently under investigation [23] .
Another interesting finding is marital status is an independent prognostic factor for G-NET. Unmarried patients were at high risk of cancer related death for G-NET. The impact of marital status on cancer survival outcome considered marriage as a means of social support [24] . Unmarried patients are often diagnosed with more advanced tumor stage, and they are also more likely to receive insufficient treatment [25] . They may also less adherence to medical interventions than married patients. The effect of marital status is being increasingly recognized as a determinant of stage at diagnosis, as well as a determinant of the prognosis of treated cancer [25] [26] [27] [28] [29] [30] [31] . To our knowledge, our study was the first to report the impact of marital status on G-NETs.
Another significant predictor of outcome was gender. The incidence of NETs is higher in female patients than in male patients [32] . The protective effect of female observed in this study is very interesting. This may be related to the abnormal expression of hormones in men and women.
There are several limitations of our present study. First, there is lack of centralized pathology review and the criteria for the diagnosis of neuroendocrine tumors also changed in the long study periods. Second, the clinical information, such as the burden of the tumors, the quality of surgery, medical therapy is missing in SEER database.
Conclusion
This large population-based study using SEER data provides an up-to-date estimate of the incidence and prognosis of G-NETs and discloses factors that may be independent prognostic factors. The survival of patients with G-NETs have increased over the past decades, but the exact cause of the observed survival increase remains to be explained.
